Related Experiment Videos
Two new severe mutations causing guanidinoacetate methyltransferase deficiency
C Carducci1, V Leuzzi, C Carducci
1Department of Experimental Medicine and Pathology, Università "La Sapienza,", Rome, Italy.
Molecular Genetics and Metabolism
|January 4, 2001
Summary
Guanidinoacetate methyltransferase deficiency, a rare creatine metabolism disorder, was identified in a child with neurological issues. Novel mutations were found, impacting gene expression and leading to disease.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Primary disorders of creatine metabolism are recently identified conditions.
- Guanidinoacetate methyltransferase (GAMT) deficiency is a rare metabolic disorder affecting creatine synthesis.
- Early diagnosis and understanding of GAMT deficiency are crucial for managing neurological symptoms.
Observation:
- A child presented with neurological regression, epilepsy, and movement disorder within the first year of life.
- High guanidinoacetic acid levels were detected in urine, plasma, and cerebrospinal fluid (CSF) via HPLC analysis.
Findings:
- Two novel mutations, c.491insG and IVS5-3C>G, were identified in the GAMT gene.
- The c.491insG mutation results in a frameshift and premature stop codon.
- The IVS5-3C>G mutation disrupts proper gene splicing and likely leads to mRNA degradation.
Implications:
- These findings expand the molecular understanding of GAMT deficiency.
- Identifying novel mutations aids in diagnosing and potentially treating creatine metabolism disorders.
- This research highlights the importance of early diagnosis for neurological conditions.